MX2013003168A - Anticuerpo contra ephrin b2 y su uso. - Google Patents

Anticuerpo contra ephrin b2 y su uso.

Info

Publication number
MX2013003168A
MX2013003168A MX2013003168A MX2013003168A MX2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A MX 2013003168 A MX2013003168 A MX 2013003168A
Authority
MX
Mexico
Prior art keywords
ephrin
antibody
lymphangiogenesis
cancer
drug
Prior art date
Application number
MX2013003168A
Other languages
English (en)
Inventor
Torrecuadrada Jorge Luis Martinez
Infantes Maria Angeles Abengozar
Original Assignee
Fundacion Ct Nac De Investigaciones Oncologicas Cnio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Ct Nac De Investigaciones Oncologicas Cnio filed Critical Fundacion Ct Nac De Investigaciones Oncologicas Cnio
Publication of MX2013003168A publication Critical patent/MX2013003168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un nuevo anticuerpo contra ephrin B2 y a su uso para detectar dicha proteína y como medicamento para inhibir la angiogénesis y la linfoangiogénesis, en el tratamiento de enfermedades en las que estos procesos están implicados como, por ejemplo, el cáncer.
MX2013003168A 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso. MX2013003168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso

Publications (1)

Publication Number Publication Date
MX2013003168A true MX2013003168A (es) 2013-08-21

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003168A MX2013003168A (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso.

Country Status (12)

Country Link
US (1) US9062109B2 (es)
EP (1) EP2620449A4 (es)
JP (1) JP2013542720A (es)
KR (1) KR20140014062A (es)
CN (1) CN103237812A (es)
AU (1) AU2011306816A1 (es)
BR (1) BR112013005977A2 (es)
CA (1) CA2812727A1 (es)
ES (1) ES2378976B1 (es)
MX (1) MX2013003168A (es)
RU (1) RU2013118454A (es)
WO (1) WO2012038573A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
US20220064285A1 (en) * 2018-12-28 2022-03-03 The General Hospital Corporation Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases
WO2020232144A1 (en) * 2019-05-14 2020-11-19 Sanford Health Anti-human ephrin b1 antibodies and uses thereof
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012360A2 (en) * 2003-07-22 2005-02-10 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
EP1954720A1 (en) * 2005-10-31 2008-08-13 The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health Antibodies and immunotoxins that target human glycoprotein nmb
TWI478938B (zh) * 2006-01-20 2015-04-01 Genentech Inc 抗-ｅｐｈｒｉｎｂ２抗體及使用該抗體的方法
PL1972637T3 (pl) * 2007-03-19 2012-01-31 Univ Stuttgart Antagoniści selektywni wobec huTNFR1
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Also Published As

Publication number Publication date
EP2620449A1 (en) 2013-07-31
BR112013005977A2 (pt) 2019-09-24
AU2011306816A1 (en) 2013-04-04
US20130287795A1 (en) 2013-10-31
ES2378976B1 (es) 2013-05-06
CN103237812A (zh) 2013-08-07
US9062109B2 (en) 2015-06-23
JP2013542720A (ja) 2013-11-28
KR20140014062A (ko) 2014-02-05
CA2812727A1 (en) 2012-03-29
WO2012038573A1 (es) 2012-03-29
ES2378976A1 (es) 2012-04-19
RU2013118454A (ru) 2014-10-27
EP2620449A4 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
HK1247567A1 (zh) 用於治療癌症的涉及針對密蛋白18.2之抗體的聯合治療
NZ630542A (en) Methods of treating a tauopathy
TN2015000396A1 (en) Antibody drug conjugates
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
HK1208152A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 182
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
GB201118656D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
WO2013114367A8 (en) C10rf32 antibodies, and uses thereof for treatment of cancer
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
GB201209613D0 (en) New compounds
TN2012000414A1 (en) Forms of rifaximin and uses thereof
SG10201903119QA (en) Polypeptide vaccine
MX366899B (es) Nuevos compuestos.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
TH137287B (th) สารชักนำอะพอพโทซิสสำหรับการรักษามะเร็งและโรคทางภูมิคุ้มกันและภูมิต้าน ตนเอง (Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases)
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
WO2013053034A3 (pt) Tiazacridinas utilizadas na terapia anticâncer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal